Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) and Deputy Programme Director for High Consequence Infectious Diseases, NHS England, is appointed MBE for services to Clinical Research. Dr Dunning led clinical trials during the terrible Ebola epidemic in West Africa.

Jake Dunning wearing PPE and standing behind the fence in an Ebola healtcare facility hot zone
Dr Jake Dunning, Honorary Visiting Research Fellow at the Centre for Tropical Medicine and Global Health, has been awarded an MBE in the New Year's Honours list. The award recognises his services to clinical research, particularly his contributions to Ebola research efforts. Jake joined the Epidemic diseases Research Group Oxford (ERGO) in October 2014, as part of the RAPIDE trial team studying potential treatments for Ebola virus disease in West Africa. The trials, led by Prof Peter Horby, evaluated two candidate drugs at Ebola treatment centres in Liberia and Sierra Leone. Jake was the Field Lead for the trials, based in West Africa, and worked with over 40 researchers from 10 countries, including doctors and nurses from the affected countries.
Following completion of the trials in 2015, Jake moved to a new full time post as Consultant in Infectious Diseases at the National Infection Service, Public Health England. However, he continues to work with ERGO on preparedness and response activities for outbreak research. Additionally, Jake is the NHS England Deputy Programme Director for High Consequence Infectious Diseases, which includes diseases such as viral haemorrhagic fever, avian influenza, and pneumonic plague. He also practises clinical infectious diseases at the Royal Free Hospital, London. Along with other trial team members, Jake received a British Government Ebola Service Medal in 2015, and his international colleagues were recognised with the award of Oxford Ebola service medals.
On receiving his award, Jake said "I am very grateful to have received this honour, mindful that I was part of a brilliant and dedicated team. Without the extraordinary support of colleagues in the field and in Oxford, these unique and very challenging trials would not have happened. We are now applying the skills and lessons learned to improving outbreak preparedness, response and research activities for high consequence infections, both overseas and in the UK. I am indebted to Peter Horby and the Centre, for having provided me with such an amazing opportunity.

The full story is available on the University of Oxford website

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Four CTMGH researchers awarded full professorships

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.